InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,483.17
(
0.34%
)
US TECH 100
19,125.20
(
-0.43%
)
Dow Jones
39,543.35
(
1.00%
)
Brent Oil
85.12
(
1.31%
)
Bitcoin
61,228.72
(
-3.06%
)
Post# of 252316
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 104010

Monday, 09/13/2010 6:48:31 AM

Monday, September 13, 2010 6:48:31 AM

Post# of 252316
I think that MRK is trying to say that even though prior nulls were excluded from RESPOND-2 study, since 25% of patients in the trial had < 1 log reduction in viral load at week 4 while in the lead, they might be considered nulls. Still, I don't think nulls will be included in boceprevir's label in opposed to telaprevir.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up